There are also some reports where CBD is either not so effective or becomes less effective for some reason. In some of these patients it is probably prudent to add some THC to their daily dosing as it has been reported to help. I would always VERY slowly increase the daily THC by 1 mg every two days.
Dr Frankel talks about Trigeminal Neuralgia and the positive effect he has seen cannabis have on patients dealing with it. Some feedback received by three recent patients is also included.
You Might Also Enjoy.
To begin with, overall, the efficacy of rich CBD dosed extracts to help treat seizures, particularly in treatment resistant seizure disorders, is well established. I have seen two children, under the age of 7 in the past two weeks alone, where their seizures, both having 3-4 grand mals per day, go to having less than one limited seizure per week. Can you imagine how this changes the life of the child as well as parents and other family members? It certainly always places a big smile on my face.
Cookie Bekkar is a cancer survivor and patient of Dr Frankel's. She has created a website to share her story, what worked well for her and as a resource help inspire/educate other patients.
“I apologize because I didn’t look hard enough, until now,” he wrote. “I didn’t look far enough. I was too dismissive of the loud chorus of legitimate patients whose symptoms improved on cannabis. Instead, I lumped them with the high-visibility malingerers, just looking to get high. I now know that. it doesn’t have a high potential for abuse, and there are very legitimate medical applications.”
“THC has been demonized again,” Josh Stanley explains. “CBD-only is not the silver bullet.”
“If your really want the full benefit of cannabis, there’s so much more out there than CBD.”
“What about the rest of the plant?” Gupta asks.
After much talk about CBD, the conversation turns to the suddenly forgotten cannabinoid, THC.
Weed 2’s medicinal cannabis patient testimonies and the fact of cannabis’ relative safety may cause one to long for some investigation by the filmmakers into the parties — if any — responsible for perpetuating the US federal government’s rejection of the medicinal value of cannabis, which makes research approval especially difficult to obtain. However, such an investigation may veer too far from Dr. Gupta’s scientific stomping ground. (He does mention in his editorial that a number of legislators — whom he does not name — contacted him following the release of Weed to voice their support or to learn more. 6 )
Many viewers may find the documentaries’ focus on these very young children to be too exclusive or emotionally manipulative — a valid argument. On the other hand, perhaps Dr. Gupta’s intent is simply to make the most powerful case he believes possible by exposing the experiences of subjects whose existences could be most visibly improved — appropriate to the medium of television — through therapeutic medicinal cannabis treatment, subjects who cannot speak for themselves and whose suffering cannot be ascribed to unhealthful life choices.
Similarly, Weed 2 focuses on two-year-old Vivian Wilson and her family, who were residents of New Jersey when Dr. Gupta’s team began documenting their story. Vivian was experiencing up to 75 seizures daily. Her family’s plight for access to medicinal cannabis for her received national attention when Vivian’s father, Brian Wilson, confronted New Jersey Governor Chris Christie about the state medical cannabis program’s constraints regarding minors at a diner during a campaign-related publicity appearance. (Once considered to be the 2016 Republican presidential candidate front-runner, Governor Christie’s already-suffering image was not helped by the footage of his terse exchange with a pleading Brian Wilson that is incorporated into Weed 2: “I know you think it’s simple. It’s simple for you; it’s not simple for me,” interrupted Governor Christie.1)
As in Weed, Weed 2 fails to place cannabis’ Schedule I designation by the US Drug Enforcement Agency (DEA) into context by providing examples of other drugs in the category, such as heroin and LSD. 1,2 Dr. Gupta better elucidated in a CNN.com editorial published in anticipation of the sequel 6 :
Patent No. 6630507 is titled “Cannabinoids as Antioxidants and Neuroprotectants.”7 The patent’s “assignee” is the United States “as represented by the Department of Health and Human Services.” According to the patent abstract, the antioxidant properties of cannabinoids make them “useful in the treatment and prophylaxis of [a] wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases,” and their function as neuroprotectants may serve to “[limit] neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease and HIV dementia.” 7
The Problem of Schedule I Classification
“In general, cannabis is very non-toxic. Unlike opiates, there is no dose of cannabis that arrests breathing, and there is a reason for this,” said Ethan Russo, MD, president of the International Cannabinoid Research Society and a senior medical advisor to GW Pharmaceuticals (email, March 27, 2014). “Most side effects of cannabis usage are attributable to THC, the primary psychoactive ingredient, which can certainly cause anxiety, panic and even temporary toxic psychosis when too much is taken, or an individual is naïve to its effects, or is simply sensitive to them.”